Free Post Earnings Research Report: Cantel Medical’s Sales Jumped 13.3%; EPS Surged 21.9%

LONDON, UK / ACCESSWIRE / January 08, 2018 / Active-Investors.com has just released a free earnings report on Cantel Medical Corp. (NYSE: CMD) ("Cantel"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CMD. The Company reported its first quarter fiscal 2018 operating results on December 07, 2017. The medical equipment maker posted record sales and earnings performance in the reported quarter. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cantel Medical most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CMD

Earnings Highlights and Summary

For the three months ended October 31, 2017, Cantel's net sales jumped 13.3% to $212.77 million on a y-o-y basis compared to $187.73 million in Q1 FY17, driven by an organic growth of 8.6%, impact from acquisitions of 4.3%, and a favorable impact from foreign currency of 0.4%. The Company's revenue numbers exceeded analysts' estimates by $5.04 million.

Cantel's international sales jumped 39.2% on a y-o-y basis, while its US business also performed well with a 6.9% growth, given tough comparable.

During Q1 FY18, Cantel's GAAP gross margin contracted 40 basis points to 47.3% compared to 47.7% in Q1 FY17, driven by both the BHT inventory step-up cost and the impact of the recast. The Company's non-GAAP gross margin expanded 90 basis points y-o-y.

For Q1 FY18, Cantel's GAAP operating expenses increased 10.5% on a y-o-y basis. The impact of acquired cost from acquisitions was roughly $2.8 million, or 4.5%. The balance was purposeful investment in-line with the Company's strategic client initiatives.

During Q1 FY18, Cantel's GAAP operating profit grew 16.9% to $31.6 million on a y-o-y basis while its non-GAAP operating profit increased 13.1% to $38.4 million on a y-o-y basis.

For Q1 FY18, Cantel's GAAP earnings per share (EPS) jumped 21.9% to $0.55 on a y-o-y basis, while its non-GAAP EPS increased 12.7% to $0.57 on a y-o-y basis. The Company's earnings surpassed Wall Street's estimates of $0.54 per share.

During Q1 FY18, Cantel's adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) came in at $44.4 million, up 10.8% on a y-o-y basis, while its adjusted EBITDA for the last 12 months was $165.3 million, up 13.1% on a y-o-y basis.

Segment Results

During Q1 FY18, Cantel's Endoscopy segment's sales grew 19.8% to approximately $112 million on a y-o-y basis, with a strong organic growth of 10.7%. The segment's recurring revenue was up 20.8%. The segment's GAAP operating profit jumped 12.1% to $19.7 million on a y-o-y basis, while its non-GAAP operating profit advanced 17.8% to $23.8 million.

During Q1 FY18, Cantel's sales in the Water Purification and Filtration segment increased 7.4% to a record $53.6 million, as a strong backlog translated into increased shipments for the reported quarter. The segment's backlog remains stable at just over $66 million. The segment's GAAP operating profit jumped 13.8% to $10.2 million, while its non-GAAP operating profit increased 13.1% to $10.6 million.

For Q1 FY18, Cantel's Healthcare Disposables segment reported a strong y-o-y growth of 5.7% to $38.9 million, all of which was organic. A favorable product mix coupled with near double-digit growth of the Company's branded portfolio drove margin expansion in this segment. The segment's GAAP operating profit jumped 20.3% to $8.9 million, while its non-GAAP operating profit increased 15.8% to $10.5 million.

Cash Matters

Cantel ended the quarter with $37.2 million in cash and cash equivalents, and $158.1 million in working capital. The Company's gross debt was $168 million at the end of the reported quarter. This included $61.3 million of borrowings to fund the acquisition of BHT. Cantel's net debt was $130.8 million, while its net debt to adjusted EBITDA was 0.79.

Stock Performance Snapshot

January 05, 2018 - At Friday's closing bell, Cantel Medical's stock slightly fell 0.36%, ending the trading session at $106.08.

Volume traded for the day: 74.83 thousand shares.

Stock performance in the last month – up 5.56%; previous three-month period – up 9.28%; past twelve-month period – up 35.36%; and year-to-date – up 3.12%

After last Friday's close, Cantel Medical's market cap was at $4.42 billion.

The stock has a dividend yield of 0.16%.

The stock is part of the Financial sector, categorized under the Exchange Traded Fund industry. This sector was up 0.5% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors